Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome.

Buhl ES, Jessen N, Pold R, Ledet T, Flyvbjerg A, Pedersen SB, Pedersen O, Schmitz O, Lund S

Diabetes1 Jul 2002Cited by 190 (Europe PMC)

PMID12086950DOI10.2337/diabetes.51.7.2199PepBankPUB-12086950

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, AICAR reduced triglycerides versus ad libitum-fed controls.
In plain wordsIn rats, AICAR reduced blood triglycerides compared with freely fed controls.
Peptide
AICAR (acadesine)
Outcome
DecreasePlasma triglycerides
Study
ratn = 12
obese Zucker fa/fa rats
Comparator
Ad libitum-fed obese controls
Outcome group
Lipids · Metabolic and weight
Studied dose
0.5 mg/g body wt daily · subcutaneous · 7 weeksAs given in this study (rat).
Source sentences
Summary
AICAR administration significantly reduced plasma triglyceride levels (P < 0.01 for AICAR vs. AL, and P = 0.05 for AICAR vs. PF) and free fatty acids (P < 0.01 for AICAR vs. AL, and P < 0.05 for AICAR vs. PF) and increased HDL cholesterol levels (P < 0.01 for AICAR vs. AL and PF).
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate whether chronic AICAR administration, in addition to the beneficial effects on insulin sensitivity, is capable of improving other phenotypes associated with the insulin resistance syndrome, obese Zucker (fa/fa) rats (n = 6) exhibiting insulin resistance, hyperlipidemia, and hypertensi…
Summary · context
Obese control rats were either pair-fed (PF) (n = 6) or ad libitum-fed (AL) (n = 6).
Report a problemFND-1208695001
02AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, AICAR reduced triglycerides versus pair-fed controls.
In plain wordsIn rats, AICAR reduced blood triglycerides compared with pair-fed controls.
Peptide
AICAR (acadesine)
Outcome
DecreasePlasma triglycerides
Study
ratn = 12
obese Zucker fa/fa rats
Comparator
Pair-fed obese controls
Outcome group
Lipids · Metabolic and weight
Studied dose
0.5 mg/g body wt daily · subcutaneous · 7 weeksAs given in this study (rat).
Source sentences
Summary
AICAR administration significantly reduced plasma triglyceride levels (P < 0.01 for AICAR vs. AL, and P = 0.05 for AICAR vs. PF) and free fatty acids (P < 0.01 for AICAR vs. AL, and P < 0.05 for AICAR vs. PF) and increased HDL cholesterol levels (P < 0.01 for AICAR vs. AL and PF).
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate whether chronic AICAR administration, in addition to the beneficial effects on insulin sensitivity, is capable of improving other phenotypes associated with the insulin resistance syndrome, obese Zucker (fa/fa) rats (n = 6) exhibiting insulin resistance, hyperlipidemia, and hypertensi…
Summary · context
Obese control rats were either pair-fed (PF) (n = 6) or ad libitum-fed (AL) (n = 6).
Report a problemFND-1208695002
03AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, AICAR reduced free fatty acids versus ad libitum-fed controls.
In plain wordsIn rats, AICAR reduced blood free fatty acids compared with freely fed controls.
Peptide
AICAR (acadesine)
Outcome
DecreaseFree fatty acids
Study
ratn = 12
obese Zucker fa/fa rats
Comparator
Ad libitum-fed obese controls
Outcome group
Lipids · Metabolic and weight
Studied dose
0.5 mg/g body wt daily · subcutaneous · 7 weeksAs given in this study (rat).
Source sentences
Summary
AICAR administration significantly reduced plasma triglyceride levels (P < 0.01 for AICAR vs. AL, and P = 0.05 for AICAR vs. PF) and free fatty acids (P < 0.01 for AICAR vs. AL, and P < 0.05 for AICAR vs. PF) and increased HDL cholesterol levels (P < 0.01 for AICAR vs. AL and PF).
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate whether chronic AICAR administration, in addition to the beneficial effects on insulin sensitivity, is capable of improving other phenotypes associated with the insulin resistance syndrome, obese Zucker (fa/fa) rats (n = 6) exhibiting insulin resistance, hyperlipidemia, and hypertensi…
Summary · context
Obese control rats were either pair-fed (PF) (n = 6) or ad libitum-fed (AL) (n = 6).
Report a problemFND-1208695003
04AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, AICAR reduced free fatty acids versus pair-fed controls.
In plain wordsIn rats, AICAR reduced blood free fatty acids compared with pair-fed controls.
Peptide
AICAR (acadesine)
Outcome
DecreaseFree fatty acids
Study
ratn = 12
obese Zucker fa/fa rats
Comparator
Pair-fed obese controls
Outcome group
Lipids · Metabolic and weight
Studied dose
0.5 mg/g body wt daily · subcutaneous · 7 weeksAs given in this study (rat).
Source sentences
Summary
AICAR administration significantly reduced plasma triglyceride levels (P < 0.01 for AICAR vs. AL, and P = 0.05 for AICAR vs. PF) and free fatty acids (P < 0.01 for AICAR vs. AL, and P < 0.05 for AICAR vs. PF) and increased HDL cholesterol levels (P < 0.01 for AICAR vs. AL and PF).
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate whether chronic AICAR administration, in addition to the beneficial effects on insulin sensitivity, is capable of improving other phenotypes associated with the insulin resistance syndrome, obese Zucker (fa/fa) rats (n = 6) exhibiting insulin resistance, hyperlipidemia, and hypertensi…
Summary · context
Obese control rats were either pair-fed (PF) (n = 6) or ad libitum-fed (AL) (n = 6).
Report a problemFND-1208695004
05AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, AICAR increased HDL cholesterol versus ad libitum-fed controls.
In plain wordsIn rats, AICAR increased HDL cholesterol compared with freely fed controls.
Peptide
AICAR (acadesine)
Outcome
IncreaseHDL cholesterol
Study
ratn = 12
obese Zucker fa/fa rats
Comparator
Ad libitum-fed obese controls
Outcome group
Lipids · Metabolic and weight
Studied dose
0.5 mg/g body wt daily · subcutaneous · 7 weeksAs given in this study (rat).
Source sentences
Summary
AICAR administration significantly reduced plasma triglyceride levels (P < 0.01 for AICAR vs. AL, and P = 0.05 for AICAR vs. PF) and free fatty acids (P < 0.01 for AICAR vs. AL, and P < 0.05 for AICAR vs. PF) and increased HDL cholesterol levels (P < 0.01 for AICAR vs. AL and PF).
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate whether chronic AICAR administration, in addition to the beneficial effects on insulin sensitivity, is capable of improving other phenotypes associated with the insulin resistance syndrome, obese Zucker (fa/fa) rats (n = 6) exhibiting insulin resistance, hyperlipidemia, and hypertensi…
Summary · context
Obese control rats were either pair-fed (PF) (n = 6) or ad libitum-fed (AL) (n = 6).
Report a problemFND-1208695005
06AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, AICAR increased HDL cholesterol versus pair-fed controls.
In plain wordsIn rats, AICAR increased HDL cholesterol compared with pair-fed controls.
Peptide
AICAR (acadesine)
Outcome
IncreaseHDL cholesterol
Study
ratn = 12
obese Zucker fa/fa rats
Comparator
Pair-fed obese controls
Outcome group
Lipids · Metabolic and weight
Studied dose
0.5 mg/g body wt daily · subcutaneous · 7 weeksAs given in this study (rat).
Source sentences
Summary
AICAR administration significantly reduced plasma triglyceride levels (P < 0.01 for AICAR vs. AL, and P = 0.05 for AICAR vs. PF) and free fatty acids (P < 0.01 for AICAR vs. AL, and P < 0.05 for AICAR vs. PF) and increased HDL cholesterol levels (P < 0.01 for AICAR vs. AL and PF).
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate whether chronic AICAR administration, in addition to the beneficial effects on insulin sensitivity, is capable of improving other phenotypes associated with the insulin resistance syndrome, obese Zucker (fa/fa) rats (n = 6) exhibiting insulin resistance, hyperlipidemia, and hypertensi…
Summary · context
Obese control rats were either pair-fed (PF) (n = 6) or ad libitum-fed (AL) (n = 6).
Report a problemFND-1208695006
07AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, AICAR lowered systolic blood pressure by 14.6 +/- 4.3 mmHg.
In plain wordsIn rats, AICAR lowered systolic blood pressure.
Peptide
AICAR (acadesine)
Outcome
DecreaseSystolic blood pressure
Study
ratn: not reported in source
obese Zucker fa/fa rats
Outcome group
Blood pressure · Cardiovascular
Studied dose
0.5 mg/g body wt daily · subcutaneous · 7 weeksAs given in this study (rat).
Measurements
Systolic pressure reduction
14.6 mmHg
AICAR
Reported variability
4.3 mmHg
type not specified
Source sentences
Summary
AICAR treatment also lowered systolic blood pressure by 14.6 +/- 4.3 mmHg (P < 0.05), and AICAR-treated animals exhibited a tendency toward decreased intra-abdominal fat content.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate whether chronic AICAR administration, in addition to the beneficial effects on insulin sensitivity, is capable of improving other phenotypes associated with the insulin resistance syndrome, obese Zucker (fa/fa) rats (n = 6) exhibiting insulin resistance, hyperlipidemia, and hypertensi…
Summary · context
Obese control rats were either pair-fed (PF) (n = 6) or ad libitum-fed (AL) (n = 6).
Report a problemFND-1208695007
08AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, AICAR showed a tendency toward decreased intra-abdominal fat.
In plain wordsIn rats, AICAR showed a tendency toward less abdominal fat.
Peptide
AICAR (acadesine)
Outcome
DecreaseIntra-abdominal fat
Study
ratn: not reported in source
obese Zucker fa/fa rats
Outcome group
Body weight · Metabolic and weight
Studied dose
0.5 mg/g body wt daily · subcutaneous · 7 weeksAs given in this study (rat).
Source sentences
Summary
AICAR treatment also lowered systolic blood pressure by 14.6 +/- 4.3 mmHg (P < 0.05), and AICAR-treated animals exhibited a tendency toward decreased intra-abdominal fat content.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate whether chronic AICAR administration, in addition to the beneficial effects on insulin sensitivity, is capable of improving other phenotypes associated with the insulin resistance syndrome, obese Zucker (fa/fa) rats (n = 6) exhibiting insulin resistance, hyperlipidemia, and hypertensi…
Summary · context
Obese control rats were either pair-fed (PF) (n = 6) or ad libitum-fed (AL) (n = 6).
Report a problemFND-1208695008
09AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, AICAR normalized the oral glucose tolerance test.
In plain wordsIn rats, AICAR normalized glucose tolerance.
Peptide
AICAR (acadesine)
Outcome
IncreaseOral glucose tolerance
Study
ratn: not reported in source
obese Zucker fa/fa rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 mg/g body wt daily · subcutaneous · 7 weeksAs given in this study (rat).
Source sentences
Summary
Furthermore, AICAR administration normalized the oral glucose tolerance test and decreased fasting concentrations of glucose and insulin close to the level of the lean animals.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate whether chronic AICAR administration, in addition to the beneficial effects on insulin sensitivity, is capable of improving other phenotypes associated with the insulin resistance syndrome, obese Zucker (fa/fa) rats (n = 6) exhibiting insulin resistance, hyperlipidemia, and hypertensi…
Summary · context
Obese control rats were either pair-fed (PF) (n = 6) or ad libitum-fed (AL) (n = 6).
Report a problemFND-1208695009
10AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, AICAR reduced fasting glucose close to lean animal levels.
In plain wordsIn rats, AICAR reduced fasting blood sugar close to levels in lean rats.
Peptide
AICAR (acadesine)
Outcome
DecreaseFasting glucose
Study
ratn: not reported in source
obese Zucker fa/fa rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 mg/g body wt daily · subcutaneous · 7 weeksAs given in this study (rat).
Source sentences
Summary
Furthermore, AICAR administration normalized the oral glucose tolerance test and decreased fasting concentrations of glucose and insulin close to the level of the lean animals.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate whether chronic AICAR administration, in addition to the beneficial effects on insulin sensitivity, is capable of improving other phenotypes associated with the insulin resistance syndrome, obese Zucker (fa/fa) rats (n = 6) exhibiting insulin resistance, hyperlipidemia, and hypertensi…
Summary · context
Obese control rats were either pair-fed (PF) (n = 6) or ad libitum-fed (AL) (n = 6).
Report a problemFND-1208695010
11AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, AICAR reduced fasting insulin close to lean animal levels.
In plain wordsIn rats, AICAR reduced fasting insulin close to levels in lean rats.
Peptide
AICAR (acadesine)
Outcome
DecreaseFasting insulin
Study
ratn: not reported in source
obese Zucker fa/fa rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 mg/g body wt daily · subcutaneous · 7 weeksAs given in this study (rat).
Source sentences
Summary
Furthermore, AICAR administration normalized the oral glucose tolerance test and decreased fasting concentrations of glucose and insulin close to the level of the lean animals.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate whether chronic AICAR administration, in addition to the beneficial effects on insulin sensitivity, is capable of improving other phenotypes associated with the insulin resistance syndrome, obese Zucker (fa/fa) rats (n = 6) exhibiting insulin resistance, hyperlipidemia, and hypertensi…
Summary · context
Obese control rats were either pair-fed (PF) (n = 6) or ad libitum-fed (AL) (n = 6).
Report a problemFND-1208695011
12AnimalAnimal study (in vivo)Mechanism
In obese Zucker rats, AICAR enhanced GLUT4 protein expression in primarily white fast-twitch muscles.
In plain wordsIn rats, AICAR increased GLUT4 protein in primarily white fast-twitch muscles.
Peptide
AICAR (acadesine)
Outcome
IncreaseGLUT4 protein expression
Study
ratn: not reported in source
obese Zucker fa/fa rats
Outcome group
Receptor activity and mechanism · Metabolic and weight
Studied dose
0.5 mg/g body wt daily · subcutaneous · 7 weeksAs given in this study (rat).
Source sentences
Summary
Finally, in line with previous findings, AICAR treatment was also found to enhance GLUT4 protein expression and to increase maximally insulin-stimulated glucose transport in primarily white fast-twitch muscles.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate whether chronic AICAR administration, in addition to the beneficial effects on insulin sensitivity, is capable of improving other phenotypes associated with the insulin resistance syndrome, obese Zucker (fa/fa) rats (n = 6) exhibiting insulin resistance, hyperlipidemia, and hypertensi…
Summary · context
Obese control rats were either pair-fed (PF) (n = 6) or ad libitum-fed (AL) (n = 6).
Report a problemFND-1208695012
13AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, AICAR increased maximally insulin-stimulated glucose transport in primarily white fast-twitch muscles.
In plain wordsIn rats, AICAR increased muscle sugar transport in response to insulin.
Peptide
AICAR (acadesine)
Outcome
IncreaseInsulin-stimulated glucose transport
Study
ratn: not reported in source
obese Zucker fa/fa rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 mg/g body wt daily · subcutaneous · 7 weeksAs given in this study (rat).
Source sentences
Summary
Finally, in line with previous findings, AICAR treatment was also found to enhance GLUT4 protein expression and to increase maximally insulin-stimulated glucose transport in primarily white fast-twitch muscles.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate whether chronic AICAR administration, in addition to the beneficial effects on insulin sensitivity, is capable of improving other phenotypes associated with the insulin resistance syndrome, obese Zucker (fa/fa) rats (n = 6) exhibiting insulin resistance, hyperlipidemia, and hypertensi…
Summary · context
Obese control rats were either pair-fed (PF) (n = 6) or ad libitum-fed (AL) (n = 6).
Report a problemFND-1208695013

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.